Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
ACADthis companyAcadia Pharmaceuticals Inc.	$21.60	11.51×	3.69×	4.22×	29.19×	-252.2%	91.7%	9.8%	36.5%	31.9%	8.1%	2.3%	0.04×	-0.83×	0×	3.83×	0.0%	4	4.87	4	A-
ANROAlto Neuroscience, Inc.	$27.89	-8.13×	3.4×	0×	-5.68×	-73.1%	0.0%	0.0%	0.0%	-41.8%	-38.2%	-10.1%	0.03×	2.86×	-26.88×	15.69×	0.0%	2	13.38	2	C+
AVXLAnavex Life Sciences Corp.	$1.19	-16.48×	8×	0×	-14.16×	2.3%	0.0%	0.0%	0.0%	-48.9%	-54.2%	-5.1%	0×	2.21×	0×	11.6×	0.0%	1	4.27	2	C
AXSMAxsome Therapeutics, Inc.	$133.82	-49.63×	102.9×	14.23×	-53.57×	-423.3%	92.6%	-26.5%	-28.7%	-207.5%	-44.0%	-1.0%	2.73×	0.49×	-25.81×	1.55×	0.0%	3	4.25	1	D+
CTNMContineum Therapeutics, Inc.	$10.00	-5.27×	1.21×	0×	-3.68×	-74.9%	0.0%	0.0%	0.0%	-23.0%	-25.3%	-17.5%	0.03×	0.99×	0×	27.5×	0.0%	2	16.76	2	C+
LBRXLB Pharmaceuticals Inc Common Stock	$42.38	-22.26×	1.87×	0×	-12.72×	-75.2%	0.0%	0.0%	0.0%	-8.4%	-9.9%	-6.3%	0.01×	9.91×	0×	41.44×	0.0%	2	25.27	2	C+
Peer median	—	-16.48×	3.4×	0×	-12.72×	-74.9%	0.0%	0.0%	0.0%	-41.8%	-38.2%	-6.3%	0.03×	2.21×	0×	15.69×	0.0%	2	13.38	2	—